Resection of Liver Metastases: A Treatment Provides a Long-Term Survival Benefit for Patients with Advanced Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis

الملخص EN

Purpose.

Nonsurgical therapies, including biotherapy, chemotherapy, and liver-directed therapy, provided a limit survival benefit for PNET patients with hepatic metastases.

With the development of liver resection technique, there was a controversy on whether to perform a liver resection for these patients.

Methods.

A computerized search was made of the Medline/PubMed, EMbase, Cochrane Library, and SinoMed (CBM) before March 2018.

A meta-analysis was performed to investigate the differences in the efficacy of liver resection and nonliver resection treatments based on the evaluation of morbidity, 30-day mortality, symptom relief rate, and 1-, 3-, and 5-year survival.

Two investigators reviewed all included articles and extracted the data of them.

The meta-analysis was performed via Review Manager 5.3 software.

Results.

A total of 13 cohort studies with 1524 patients were included in this meta-analysis.

Compared with the nonliver resection group, liver resection group had a longer 1-, 3-, and 5-year survival time and a higher symptom relief with an acceptable mortality and morbidity.

Conclusions.

Liver resection is a safe treatment and could significantly prolong the long-term prognosis for highly selected patients with resectable liver metastases from PNET.

Further randomized, controlled trials are needed.